ElastiMed is developing a compression stocking, made from smart materials, that mimics rhythmic calf muscle contractions and stimulates blood flow. 

There is a clear need in the compression therapy market for increased compliance, which improves treatment and prevents symptoms such as swelling, blood clots, and leg ulcers from returning.

The ElastiMed Opportunity

  • $3.3 billion medical compression market
  • Large target market
    • 40% of the global adult population suffer from chronic venous insufficiency (CVI, impaired functionality of valves in the legs)
    • United States and EU: 790,000 people annually suffer from deep vein thrombosis (DVT); in the United States, 3 million people suffer from chronic lymphedema (damage to the lymph nodes often caused by surgery or cancer treatment)
  • Improves compliance
  • Highly effective, easy-to-wear, affordable treatment option
  • Functional prototype of the stocking

ElastiMed’s Novel Product

ElastiMed is developing a compression stocking, made from smart materials, that mimics rhythmic calf muscle contractions and stimulates blood flow. Based on proprietary technology that utilizes Electro-Active Polymers (EAPs), ElastiMed’s stocking stretches and contracts when stimulated by an electric pulse (generated by a 3V battery).

These unique characteristics, combined with low-cost materials and a high level of control, enable the ElastiMed stocking to provide patients with a highly effective, easy-to-wear, and affordable treatment option. Read more about the idea behind the ElastiMed stocking.

The Team

ElastiMed CEO Omer Zelka

ElastiMed Founder and CEO Omer Zelka

  • Omer Zelka, Founder and CEO: Extensive experience with electro-active materials; engineer, Intel Corporation; BSc, electrical engineering, Ben-Gurion University of the Negev
  • Vered Shuster Ben Yosef, PhD., R&D Lab Manager: ‪5 years R&D experience with medical device and pharmaceutical companies‬; PhD, biotechnology, Technion-Israel Institute of Technology
  • Omer Shem-Tov, R&D Engineer: Over 20 years of experience in developing and bringing medical devices to market; specialized in optimizing and scaling up production (Medinol, Motus GI Medical)
  • Shai Buber, Executive Board Member: Private investor; former GM (Israel) and SVP, Paradigm (sold to Apax for $1 billion in 2012), and CEO, Odigo (acquired by Comverse for $20 million in 2002); former corporate attorney, Skadden Arps, New York City; LLM, NYU School of Law; LLB, Hebrew University of Jerusalem

Trendlines’ directors: Todd Dollinger, Shahar Harari

Scientific Advisory Board

  • Daniel Clair, MD: Chairman, Department of Surgery, Palmetto Health/University of South Carolina School of Medicine; former chairman, Vascular Surgery, Cleveland Clinic
  • Prof. Gal deBotton: Professor, mechanical engineering and biomedical engineering,  Ben-Gurion University of the Negev; president, Israel Society for Theoretical and Applied Mechanics; former chairperson, Biomedical Engineering Department, Ben-Gurion University; expert in electroactive materials, mechanics of soft tissues, composite materials, and solid mechanics
  • Moshe Halak, MD: Director, Vascular & Endovascular Surgery Department, Sheba Medical Center
  • Thomas Serena, MD: Vascular surgeon; CEO & Founder, SerenaGroup; president-elect, Association for the Advancement of Wound Care (AAWC); past president, American Professional Wound Care Association; VP, American College of Hyperbaric Medicine
  • Wolfgang Vanschidt, MD: Dermatologist; professor, dermatology and phlebology,  owner, Medical Consult Freiburg; CEO, AMED Freiburg; former VP, Department of Dermatology, University of Freiburg


Founded: July 2015
Stage: Technology development
Investors: The Trendlines Group, Pix Vine Capital, private investor, strategic investor
IP: Approved U.S. patent


In the Media

Background & Market

A 60% noncompliance rate for existing treatment options. Chronic leg swelling (edema), which is caused by poor circulation, affects more than 7.4 million people in the United States alone1. Edema may result from old age, cancer treatments, poor diet or pregnancy. Blood clots, which are formed in the legs (DVT, deep vein thrombosis), affect over 790,000 people in the United States and EU2. Applying constant or changing external pressure on the legs has been proven to be a highly effective treatment to improve circulation and reduce swelling3. With a more than 60% non-compliance4 rate for existing treatment options, ElastiMed’s device is aimed at improving patient compliance with a comfortable, highly effective clinical treatment.

An estimated $3 billion market. ElastiMed addresses a potential global market of $3.3 billion. Leading players include BSN Medical, DJO, Medi, Medtronic, Sigvaris, Tactile Medical.


  1. Medical News Today 2017, Lymphatic network 2017.
  2. Aspen Pharma 2015, CDC 2015.
  3. National Center for Biotechnology Information 2015.
  4. Compliance with Compression Stockings in Chronic Venous Disease. Phlebolymphology 2007.



See ElastiMed on Reuters Video.

Watch Omer Zelka's interview on Start-Up Stadium (Hebrew).

See Omer Zelka's interview on ILTV.

See the company one-page description in Chinese (PDF).

CEO Omer Zelka presents ElastiMed.

Active compression stocking made from smart materials
ElastiMed's active compression stocking mimics rhythmic calf muscle contractions and stimulates blood flow.


Omer Zelka, Founder & CEO

ElastiMed logo
Easy-to-wear compression stocking made from smart materials

Font Resize